-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2013 to Q2 2024.
- Lineage Cell Therapeutics, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $0.000.
- Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2023 was -$1.8M, a 433% decline from 2022.
- Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2022 was $541K.
- Lineage Cell Therapeutics, Inc. annual Income Tax Expense (Benefit) for 2020 was -$1.24M, a 83.3% increase from 2019.
Income Tax Expense (Benefit), Quarterly (USD)